Production (Stage)
Heron Therapeutics, Inc.
HRTX
$2.12
$0.020.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.61% | 24.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.61% | 24.29% | |||
| Cost of Revenue | -19.92% | -3.71% | |||
| Gross Profit | 2.89% | 44.94% | |||
| SG&A Expenses | 7.81% | -0.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.35% | -1.77% | |||
| Operating Income | -24.42% | 193.61% | |||
| Income Before Tax | -28.06% | 175.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.06% | 175.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.06% | 175.56% | |||
| EBIT | -24.42% | 193.61% | |||
| EBITDA | -22.07% | 222.62% | |||
| EPS Basic | -28.03% | 175.39% | |||
| Normalized Basic EPS | -52.86% | 214.65% | |||
| EPS Diluted | -58.16% | 175.39% | |||
| Normalized Diluted EPS | -63.00% | 214.65% | |||
| Average Basic Shares Outstanding | 0.22% | 0.21% | |||
| Average Diluted Shares Outstanding | 28.58% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||